TubeMogul Inc (NASDAQ:TUBE), the enterprise software company today announced a new partnership with comScore (SCOR) to deliver TV-comparable metrics to brand advertisers. The partnership brings SCOR's vCE directly into the TubeMogul platform, providing advertisers and agencies with campaign metrics such as demographics, reach/frequency and human gross rating points, for their video campaigns. The metrics also determine which ads are received by actual people - rather than bots or spiders. TubeMogul Inc (NASDAQ:TUBE) has traded within a 52-week range of $8.15 to $14.70 a share, declining less than 1% since its July 18 initial public offering of stock through Friday's close.Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares climbed to a fresh all-time high Tuesday, after the biopharmaceutical company said it has initiated a Phase 1/2 multicenter study of AG-221 in patients with advanced solid tumors, including gliomas, as well as angioimmunoblastic T-cell lymphoma that carry an isocitrate dehydrogenase-2 mutation. AG-221 is a part of AGIO's global strategic collaboration with Celgene (CELG), a biotechnology company. In June 2014, CELG exercised its exclusive option to license AG-221. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares were up 6.6% at $77.73 recently, after climbing to the new high of $73.87. CELG shares were up 2.5% at $94.30, nearing its 52-week high of $96.50.The trial is designed to assess the clinical activity, safety and tolerability of AG-221 among patients who have an IDH2-mutant advanced solid tumor. Key objectives include describing the dose-limiting toxicities and determining the maximum tolerated dose, evaluating the pharmacokinetic and pharmacodynamics, and characterizing the clinical activity of AG-221. The study will enroll patients who have recurred or progressed following standard therapy or haven't responded to prior standard therapy. This is the second trial to be initiated in patients with cancer as part of AG-221's clinical development program, which includes the ongoing Phase 1 trial with four expansion cohorts in patients with hematologic malignancies. Under the terms of the agreement with Celgene, CELG gained worldwide development and commercialization rights for AG-221. AGIO continues to conduct early clinical development and regulatory activities within the AG-221 development program in collaboration with CELG.Royal Gold, Inc USA) (NASDAQ:RGLD) said its RGLD Gold unit has entered into a $175 million gold stream transaction with Euromax Resources that will finance a significant portion of the construction of the Ilovitza gold-copper project in Macedonia. Under the accord, Royal Gold will make two advance deposit payments totaling $15 million towards completion of the definitive feasibility study on the Ilovitza project, followed by a third payment of $160 million towards project construction. In return, Euromax will deliver 25% of any gold produced from the Ilovitza project until 525,000 ounces have been delivered, and 12.5% thereafter at a purchase price per ounce for Royal Gold of 25% of the spot price at time of delivery. Production is expected to begin in 2018. Royal Gold, Inc USA) (NASDAQ:RGLD) shares are up 1.3% in early trading at $68.97 with a 52-week spread of $42.56 - $82.84.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
